Yale taps Genesis CRO for drug discovery services

By Maggie Lynch

- Last updated on GMT

(Image: Getty/f11photo)
(Image: Getty/f11photo)

Related tags CRO Drug discovery Research and development Research

Yale University is partnering with CROs to provide drug discovery services to awardees of the Blavatnik Fund for Innovation – which aims to bridge the gap between early-stage research and product development.

The new partnership will bring Genesis Biotechnology Group (GBG) and its contract research organization (CRO) arm, Genesis Drug Discovery & Development (GD3), together with Yale to provide drug discovery services to researchers at the university.

GD3’s service providers include PharmOptima – after an acquisition​ in 2017 – Invivotek, and Venenum Biodesign.

According to William Wiesler, director of new ventures at the office of cooperative research at Yale University, the $25m Blavatnik Fund for Innovation was designed to bridge the gap from life science research to business. The fund will invest up to $300,000 per project to conduct experiments that prospective industry partners view as critical.

“It is the intent of the fund that most of the work be done outside of Yale at highly regarded CRO’s that are trusted by pharmaceutical companies and biotech investors. Genesis Biotech Group was chosen as Yale’s newest partner to provide these services on the basis of their strong reputation, breadth of services, and high-quality engagement with Yale Faculty,” ​said Wiesler.

Yale faculty will be able to, therefore, explore ideas with members of the Genesis Biotech group to develop research plans in collaboration, explained Wiesler.

He also stated that Yale labs have had a number of breakthrough medical products receive approval.

“Yale’s pharmaceutical pipeline boasts five marketed drugs and 20 in clinical development,” ​said Weisler. Partnerships, like that of GBG, are expected to grow the pipeline and advance more projects through preclinical development into trials. 

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us